{"ticker": {"uuid": "8d12cd2a-c49b-4916-8602-96180e4947e4", "symbol": "688319", "name": "Chengdu Olymvax Biopharmaceuticals Inc.", "exchange": "SHH", "country": "CN", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Price to book forward of Chengdu Olymvax Biopharmaceuticals Inc. Class A \u2013 SSE:688319", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxOQ0RMU1BDTzVMbXJ5WTJ5Z3J6ck9iaFNVV0pyS01SUUl4Z0N3TGJoc3VnNjdPdU5NTncwNWhhRkFmZFhnWWVibTVsbVJ2WmRHZEZpQXllMzlKNGNDbDR4VC15RUQ3clNPNVgwOEVRMnp0M0VxNzNrcGpORDBaWWg5aHgyRE1LQk93b3pGZTExNGNXN2RHZlRaSDVvTQ?oc=5", "source_name": "TradingView", "published_at": "2026-07-18T09:44:40+00:00", "published_display": "18 Jul 2026 09:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chengdu Olymvax Biopharmaceuticals Inc (SHSE:688319) Share Price", "summary": "", "url": "https://news.google.com/rss/articles/CBMie0FVX3lxTE9KQnM5TXRwbk5IalE4VDNBWENmZ2IyU05xMENMb3JnNXhjeFo2WXNfcHdRd1BzWkNzeEFSU1hIUV9USFdCNV95YkNoVnZpSG0weS14VUxrempNYkxyM29yX2xIWlBlVmJkVXRBQXVBODVEQjA3QU05Vjl0OA?oc=5", "source_name": "Morningstar Australia", "published_at": "2025-05-05T20:13:43+00:00", "published_display": "05 May 2025 20:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chengdu Olymvax Biopharmaceuticals Inc.\u2019s Net Profit Dropped 26.7% in First Half of 2022", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxOa1RPYWt5NHpIamMwMXlsUTFjclUxV3gzNVVsRWVjWXdlYW8yM2J1RzItR281bmc4dzIwbXRwUHN1aFBySU5LbXRrRHpfclF5VFc5RWFLY20yQ1FoVl9zcjdCQW02THFkTHhEOWdMaGF2UTdMMHhLeDVtYklMcE1aRjBLdEFSRnprZEp4TnJHRWppQzBuVGFTTlpTcmpXUUViNUNRYTZleDJ4clpUamdJUjBDZi1qOFdERlYwWjZxa1pCN2gzTldCa0JqMGZ5TndoX1lkalVB?oc=5", "source_name": "Caixin Global", "published_at": "2022-08-19T07:00:00+00:00", "published_display": "19 Aug 2022 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Price to book forward of Chengdu Olymvax Biopharmaceuticals Inc. Class A \u2013 SSE:688319", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxOQ0RMU1BDTzVMbXJ5WTJ5Z3J6ck9iaFNVV0pyS01SUUl4Z0N3TGJoc3VnNjdPdU5NTncwNWhhRkFmZFhnWWVibTVsbVJ2WmRHZEZpQXllMzlKNGNDbDR4VC15RUQ3clNPNVgwOEVRMnp0M0VxNzNrcGpORDBaWWg5aHgyRE1LQk93b3pGZTExNGNXN2RHZlRaSDVvTQ?oc=5", "source_name": "TradingView", "published_at": "2026-07-18T09:44:40+00:00", "published_display": "18 Jul 2026 09:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chengdu Olymvax Biopharmaceuticals Inc (SHSE:688319) Share Price", "summary": "", "url": "https://news.google.com/rss/articles/CBMie0FVX3lxTE9KQnM5TXRwbk5IalE4VDNBWENmZ2IyU05xMENMb3JnNXhjeFo2WXNfcHdRd1BzWkNzeEFSU1hIUV9USFdCNV95YkNoVnZpSG0weS14VUxrempNYkxyM29yX2xIWlBlVmJkVXRBQXVBODVEQjA3QU05Vjl0OA?oc=5", "source_name": "Morningstar Australia", "published_at": "2025-05-05T20:13:43+00:00", "published_display": "05 May 2025 20:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chengdu Olymvax Biopharmaceuticals Inc.\u2019s Net Profit Dropped 26.7% in First Half of 2022", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxOa1RPYWt5NHpIamMwMXlsUTFjclUxV3gzNVVsRWVjWXdlYW8yM2J1RzItR281bmc4dzIwbXRwUHN1aFBySU5LbXRrRHpfclF5VFc5RWFLY20yQ1FoVl9zcjdCQW02THFkTHhEOWdMaGF2UTdMMHhLeDVtYklMcE1aRjBLdEFSRnprZEp4TnJHRWppQzBuVGFTTlpTcmpXUUViNUNRYTZleDJ4clpUamdJUjBDZi1qOFdERlYwWjZxa1pCN2gzTldCa0JqMGZ5TndoX1lkalVB?oc=5", "source_name": "Caixin Global", "published_at": "2022-08-19T07:00:00+00:00", "published_display": "19 Aug 2022 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 57, "total_relevant": 3, "sentiment_summary": {"positive": 1, "negative": 0, "neutral": 2, "score": 54, "total": 3, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 68, "events": [{"event": "general", "label": "Market update", "weight": 1.45, "count": 2}, {"event": "earnings", "label": "Earnings", "weight": 0.55, "count": 1}], "positive_events": 1, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 30.41, "latest_week": "2026-07-17", "one_week_move": -31.5, "four_week_move": -14.8, "twelve_week_move": 6.8, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.295829, "market_dynamics_buy_signal": false, "relative_strength": 11.929504, "fair_value_gap": 66.3, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 51.8029, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-31.5% over one week, -14.8% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 59, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 1}, {"label": "Morningstar Australia", "count": 1}, {"label": "Caixin Global", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 3}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 2}, {"label": "Earnings", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "68/100 classification confidence."}, {"label": "Company focus", "value": "3", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-31.5% over one week, -14.8% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Price to book forward of Chengdu Olymvax Biopharmaceuticals Inc. Class A \u2013 SSE:688319"}], "updated_at": "2026-07-24T12:54:59.592107+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}